Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tislelizumab Combined With Liposomal Doxorubicin and Ifosfamide as First-line Treatment for Patients With Specified Subtypes of Unresectable or Metastatic Soft Tissue Sarcoma: a Multi-center, Single-arm, Prospective Phase II Clinical Trial

NCT06849986 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06849986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06849986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tislelizumab Combined With Liposomal Doxorubicin and Ifosfamide as First-line Treatment for Patients With Specified Subtypes of Unresectable or Metastatic Soft Tissue Sarcoma: a Multi-center, Single-arm, Prospective Phase II Clinical Trial
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
February 25, 2025
Completion date
December 31, 2029
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angiosarcoma, desmoplastic small round cell tumor, fibrosarcoma, leiomyosarcoma, malignant peripheral nerve sheath tumor (mpnst), pleomorphic liposarcoma, soft tissue sarcomas